BioSig Technologies Commitment toward Quality Patient Care

Information technology has made significant contributions to our world, especially in the medical industry. Medical technology has evolved from introducing doctors to new equipment to use inside private practices and hospitals to connecting patients and doctors thousands of miles away through telecommunications. Even more, medical scientists and physicians are constantly conducting research and testing new procedures to help prevent, diagnose, and cure diseases as well as developing new drugs and medicines that can lessen symptoms or treat ailments.

For example, BioSig Technologies, a Connecticut-based medicaltechnology company working on advanced biomedical signal processing technology, has been able to improve fidelity of acquired cardiac signals that may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and efficiency of the EP studies and related procedures. BioSig’s commitment toward offering higher quality of patient care by introducing innovative technological solutions to medicine, has yield some impressive growth in the medical device sector.

With more and more hospitals and practices using medical technology like mobile devices on the job, physicians can now have access to any type of information they need – from drug information, research and studies, patient history or records, and more – within mere seconds.  

Last November, BioSig had signed a research program deal with Mayo Clinic which consisted of several two-to-three-year projects, focusing on the development of additional advanced features of their first product, the PURE EP system, within the field of electrophysiology. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. 

BioSig’s ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia.

Led by their CEO Ken Londoner, a proven management team and a veteran Board of Directors, BioSig Technologies is preparing to commercialize its PURE  EPTM System. The technology has been developed to address an unmet need in a large and growing market. BioSig is currently focusing on the development of a proprietary biomedical signal processing platform, engineered to meet excess demand for technology in the electrophysiology (EP) marketplace.

PURE EP™ Simulator Gets a U.S. Patent

On June 06, 2019, BioSig Technologies, Inc., a Westport, Conn.-based company that develops a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that the U.S. Patent & Trademark Office allowed a U.S. patent application covering its electrophysiology simulator. The patent application number 15/103,278 entitled, "Systems and Methods For Evaluation of Electrophysiology Systems" was filed on June 9, 2016.

The BioSig Tech PURE EP System Aims for Arrhythmia Market

After nearly a decade of research and development, BioSig Tech could be poised to break into the nearly $5 billion global electrophysiology market.

In the spring of 2018, the West Los Angeles-based medical device company has filed for federal approval for a medical device that can help doctors target the cells that cause arrhythmias, or irregular heartbeats, which increase the risks of cardiac problems and stroke.

This biomedical device, called PURE EP, aims to cut through the background noise of the operating room and its equipment in order to allow doctors to pinpoint parts of the heart that cause atrial fibrillation and ventricular tachycardia.